The changes that could have a significant impact on immunotherapy included upregulation of let-7d (member of anti-inflammatory and tolerogenic let-7 family), miR-143 (increasing FOXp3 expression and repressing IL-13), and miR-34b (downregulated by IL-13 in AR and asthma) and downregulation of miR-375 (regulating production of IL-13), miR-342 (regulating NFκβ expression and function of Treg cells), and miR-182 (regulator of Th17 and Treg cell function) [98]. This evidence concerns the gene IL13 and asthma.